Role of colony stimulating factors (CSFs) in solid tumours: Results of an expert panel

Critical Reviews in Oncology/Hematology

Volumn 63, Issue 1, 2007, Pages 53-64

  Gridelli, Cesare ^a   Aapro, Matti S ^b   Barni, Sandro ^c   Beretta, Giordano Domenico ^d   Colucci, Giuseppe ^e   Daniele, Bruno ^f   Del Mastro, Lucia ^g   Di Maio, Massimo ^h   De Petris, Luigi ⁱ   Perrone, Francesco ^h   Thatcher, Nick ^j   De Marinis, Filippo ⁱ  

^a S G MOSCATI HOSPITAL   (Italy)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c TREVIGLIO HOSPITAL   (Italy)

^d S Orsola Hospital   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^f G RUMMO HOSPITAL   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^j CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

Colony stimulating factors; Febrile neutropenia; Guidelines; Pegfilgrastim

Indexed keywords

CISPLATIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

BREAST CANCER; CHEMOTHERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; FEBRILE NEUTROPENIA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PROPHYLAXIS; REVIEW; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; COLONY-STIMULATING FACTORS; COLORECTAL NEOPLASMS; FEMALE; FEVER; FILGRASTIM; HUMANS; LUNG NEOPLASMS; MALE; NEUTROPENIA; PRACTICE GUIDELINES;

EID: 34249321319     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.01.008     Document Type: Review

References (66)

1. Pizzo P.A. Fever in immunocompromised patients. N Engl J Med 341 (1999) 893-900
2. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12 (1994) 2471-2508
3. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 (2006) 3187-3205
4. Aapro M.S., Cameron D.A., Pettengell R., Bohlius J., Crawford J., Ellis M., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 (2006) 2433-2453
5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Myeloid Growth Factors. V.1.2006. http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf.
6. Greil R., and Jost L.M. ESMO recommendations for the application of hematopoietic growth factors. Ann Oncol 16 Suppl 1 (2005) i80-i82
7. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14 (1996) 1957-1960
8. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., et al. update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18 (2000) 3558-3585
9. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325 (1991) 164-170
10. Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzemeier U., Lebeau B., et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A (1993) 319-324
11. Pettengell R., Gurney H., Radford J.A., Deakin D.P., James R., Wilkinson P.M., et al. Granulocyte colony stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80 (1992) 1430-1436
12. Phillips K.A., and Tannock I.F. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 16 (1998) 3179-3190
13. Johnson D.H., Einhorn L.H., Birch R., Vollmer R., Perez C., Krauss S., et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5 (1987) 1731-1738
14. Hanna N., Bunn Jr. P.A., Langer C., Einhorn L., Guthrie Jr. T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (2006) 2038-2043
15. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., Tjulandin S.A., Barajas-Figueroa L.J., Wiens B.L., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23 (2005) 1178-1184
16. Timmer-Bonte J.N., de Boo T.M., Smit H.J., Biesma B., Wilschut F.A., Cheragwandi S.A., et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 23 (2005) 7974-7984
17. Lyman G.H., Lyman C.G., Sanderson R.A., and Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85 (1993) 488-493
18. Uyl-de Groot C.A., Vellenga E., and Rutten F.F. An economic model to assess the savings from a clinical application of haematopoietic growth factors. Eur J Cancer 32A (1996) 57-62
19. Calhoun E.A., Schumock G.T., McKoy J.M., Pickard S., Fitzner K.A., Heckinger E.A., et al. Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited. Pharmacoeconomics 23 (2005) 767-775
20. Lyman G.H. Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol 30 4 Suppl 13 (2003) 10-17
21. Lyman G.H., and Kuderer N.M. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 50 (2004) 129-146
22. Esser M., and Brunner H. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 21 (2003) 1295-1313
23. Berghmans T., Paesmans M., Lafitte J.J., Mascaux C., Meert A.P., Jacquy C., et al. Therapeutic use of granulocyte and granulocyte macrophage colony-stimulating factors in febrile neutropenic cancer patients: a systematic review of the literature with meta-analysis. Support Care Cancer 10 (2002) 181-188
24. Clark O.A., Lyman G.H., Castro A.A., Clark L.G., and Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23 (2005) 4198-4214
25. Garcia-Carbonero R., Mayordomo J.I., Tornamira M.V., Lopez-Brea M., Rueda A., Guillem V., et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 93 (2001) 31-38
26. Martin M., Pienkowski T., Mackey J., Pawlicki M., Guastalla J.P., Weaver C., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 (2005) 2302-2313
27. Holmes F.A., O'Shaughnessy J., Vukelja S., Jones S.E., Shogan J., Savin M., et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20 (2002) 727-731
28. Green M.D., Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14 (2003) 29-35
29. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., and Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332 (1995) 901-906
30. Wood W.C., Budman D.R., Korzun A.H., Cooper M.R., Younger J., Hart R.D., et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330 (1994) 1253-1259
31. Budman D.R., Berry D.A., Cirrincione C.T., Henderson I.C., Wood W.C., Weiss R.B., et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90 (1998) 1205-1211
32. Citron M.L., Berry D.A., Cirrincione C.T., Hudis C., Winer E.P., Gradishar W.J., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 (2003) 1431-1439
33. Hudis C., Citron M., Berry D., Cirrincione C., Gradishar W., Davidson N., et al. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Proceedings of the San Antonio Breast Cancer Symposium (2005) abstr 41
34. Venturini M., Del Mastro L., Aitini E., Baldini E., Caroti C., Contu A., et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 97 (2005) 1724-1733
35. Del Mastro L., Bruzzi P., Nicolo G., Cavazzini G., Contu A., D'Amico M., et al. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer 93 (2005) 7-14
36. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14 (1996) 2590-2611
37. Saarto T., Blomqvist C., Rissanen P., and Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75 (1997) 301-305
38. Poikonen P., Saarto T., Lundin J., Joensuu H., and Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80 (1999) 1763-1766
39. Mayers C., Panzarella T., and Tannock I.F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91 (2001) 2246-2257
40. Cameron D.A., Massie C., Kerr G., and Leonard R.C.F. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89 (2003) 1837-1842
41. Di Maio M., Gridelli C., Gallo C., and Perrone F. Viewpoint: chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?. Nat Clin Pract Oncol 3 (2006) 2-3
42. Del Mastro L., Venturini M., Lionetto R., Carnino F., Guarneri D., Gallo L., et al. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol 19 (2001) 2213-2221
43. Capotorto A.M., Pavesi L., Pedrazzoli P., Da Prada G.A., Zamagni C., Massidda B., et al. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma. J Chemother 15 (2003) 184-191
44. Bronchud M.H., Scarffe J.H., Thatcher N., Crowther D., Souza L.M., Alton N.K., et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56 (1987) 809-813
45. Adams J.R., Lyman G.H., Djulbegovic B., Feinglass J., and Bennett C.L. G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother 3 (2002) 1273-1281
46. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002) 85-91
47. Jackman D.M., and Johnson B.E. Small-cell lung cancer. Lancet 366 (2005) 1385-1396
48. Woll P.J., Hodgetts J., Lomax L., Bildet F., Cour-Chabernaud V., and Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13 (1995) 652-659
49. Thatcher N., Girling D.J., Hopwood P., Sambrook R.J., Qian W., and Stephens R.J. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial-Medical Research Council Lung Cancer Working Party. J Clin Oncol 18 (2000) 395-404
50. Ardizzoni A., Tjan-Heijnen V.C., Postmus P.E., Buchholz E., Biesma B., Karnicka-Mlodkowska H., et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 20 (2002) 3947-3955
51. Lorigan P., Woll P.J., O'Brien M.E., Ashcroft L.F., Sampson M.R., and Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 97 (2005) 666-674
52. Berghmans T., Paesmans M., Lafitte J.J., Mascaux C., Meert A.P., and Sculier J.P. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 37 (2002) 115-123
53. Grossi F., and Tiseo M. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol 58 (2006) 221-230
54. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update. J Clin Oncol 22 (2004) 330-353
55. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., and Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292 (2004) 470-484
56. Gridelli C., Aapro M., Ardizzoni A., Balducci L., De Marinis F., Kelly K., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an International Expert Panel. J Clin Oncol 23 (2005) 3125-3137
57. Di Maio M., Gridelli C., Gallo C., Shepherd F., Piantedosi F.V., Cigolari S., et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6 (2005) 669-677
58. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
59. Gridelli C., Gallo C., Di Maio M., Barletta E., Illiano A., Maione P., et al. A randomised clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second-line treatment of non-small-cell lung cancer. The Distal 01 Study. Br J Cancer 91 (2004) 1996-2004
60. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
61. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
62. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.R., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
63. Goldberg R.M., Tabah-Fisch I., Bleiberg H., de Gramont A., Tournigand C., Andre T., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 (2006) 4085-4091
64. Leonard G.D., Brenner B., and Kemeny N.E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23 (2005) 2038-2048
65. Leichman L. Neoadjuvant chemotherapy for disseminated colorectal cancer: changing the paradigm. J Clin Oncol 24 (2006) 3817-3818
66. Crawford J. Pegfilgrastim: the promise of pegylation fulfilled. Ann Oncol 14 (2003) 6-7